NCT02015481View on ClinicalTrials.gov

Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Oculopharyngeal Muscular Dystrophy
Interventions
DRUG

Cabaletta

Trial Locations (4)

90095

UCLA, Los Angeles

91120

Hadassah medical center, Jerusalem

92868

Tahseen Mozaffar, Orange

H3A 2B4

Montreal Neurological Institute, McGill University, Montreal

Sponsors
All Listed Sponsors
lead

Bioblast Pharma Ltd.

INDUSTRY

NCT02015481 - Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients | Biotech Hunter | Biotech Hunter